AD-2282 / Yuhan Corp - LARVOL DELTA

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282 (clinicaltrials.gov) - P3 | N=129 | Completed | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Completed

Trial completion • Dyslipidemia • Metabolic Disorders

A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Completed | Trial completion date: Apr 2025 ➔ Aug 2025 | Initiation date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Apr 2025 ➔ Aug 2025

Trial completion • Trial completion date • Trial initiation date • Trial primary completion date • Dyslipidemia

A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Addpharma Inc.

New P1 trial • Dyslipidemia